Teewinot Laboratories

Teewinot Laboratories was a biotechnology company focused on the biosynthetic production of cannabinoids. The company developed a proprietary biocatalysis platform, known as Cannabiosynthesis, to manufacture high-purity, pharmaceutical-grade cannabinoids including rare variants like CBG and THCV. By using enzymatic processes rather than plant extraction or traditional chemical synthesis, Teewinot aimed to provide a more scalable and consistent supply of cannabinoids for medical research and product development. The company held an extensive intellectual property portfolio covering the enzymatic production of various cannabinoid molecules. Despite its technological advancements, the company faced significant financial and legal challenges, leading to a Chapter 11 bankruptcy filing in late 2019.